BiotechTube

Simufilam

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Nov 7, 2022 → Jan 31, 2025

NCT ID
NCT05575076

About Simufilam

Simufilam is a phase 3 stage product being developed by Cassava Sciences for Alzheimer Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05575076. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (5)

NCT IDPhaseStatus
NCT06390410Phase 1Completed
NCT06195319Phase 1Completed
NCT05575076Phase 3Terminated
NCT05352763Phase 2Terminated
NCT04932655Phase 1Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25

Other Products from Cassava Sciences

Simufilam + PlaceboPhase 3
69
Simufilam + PlaceboPhase 3
69
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tabletPhase 2
44
Simufilam 100 mg oral tablet + PlaceboPhase 2
44
PTI-125, 100 mg tabletsPhase 2
44